United Kingdom DNA and Gene Cloning Services Market

United Kingdom DNA and Gene Cloning Services Market Size & Forecast:

• United Kingdom DNA and Gene Cloning Services Market Size 2025: USD 182.4 Million
• United Kingdom DNA and Gene Cloning Services Market Size 2033: USD 653.8 Million
• United Kingdom DNA and Gene Cloning Services Market CAGR: 17.31%
• United Kingdom DNA and Gene Cloning Services Market Segments: By Service (Gene Synthesis, Molecular Cloning, Plasmid Preparation, Sequencing, Custom DNA Services, Others); By End User (Pharmaceutical Companies, Biotechnology Firms, Academic Institutes, CROs, Others).

United Kingdom DNA and Gene Cloning Services Market Summary

The United Kingdom DNA and Gene Cloning Services Market was valued at USD 182.4 Million in 2025. It is forecast to reach USD 653.8 Million by 2033. That is a CAGR of 17.31% over the period.

The UK DNA & Gene Cloning Services Market provides an opportunity for pharmaceutical companies, biotechnology companies, academic laboratories, and contract research organizations to access external help in designing, constructing, cloning, and validating genetic constructs that are utilized in drug discovery, vaccine development, diagnostics, and synthetic biology research. The outsourcing of such services not only reduces the time taken during the experiment but also allows access to expertise and advanced laboratories. Over the past five years, the market has moved from conventional gene cloning to advanced automation and sequencing in high-throughput systems in biological research. The spread of the COVID-19 virus has accelerated this change because of the need for rapid gene construct design and scaling of molecular biology operations. With the increased pipelines of biologics, cell and gene therapies, and precision medicines, research organizations have increasingly resorted to outsourcing molecular engineering services.

Key Market Insights

• The UK DNA and Gene Cloning Services Market will grow with the increasing rate of outsourcing due to the advancement in pharmaceutical inventions, cell and gene therapy studies, and synthetic biology projects.
• Pharmaceutical firms will continue to be the biggest revenue generators, whereas automated DNA and cloning technologies will fuel the growth of this market throughout the forecast period.
• England will hold around 78% share of the total revenue generated by the United Kingdom DNA and Gene Cloning Services Market in 2025 because of prominent research centers and investments in biotechnology in this region.
• Scotland will be the fastest growing regional market in the forecast period due to increased innovation in life sciences and genomics research at universities.
• Gene Synthesis will be the dominant segment of the UK DNA and Gene Cloning Services Market as it will contribute about 32% share in 2025.
• Molecular Cloning forms the second-highest service segment due to its wide application in recombinant protein production and functional genomics studies.
• Custom DNA Services will witness the highest CAGR until 2032 owing to their increasing adoption in personalized research workflow and synthetic biology.
• Drug Discovery and Development will account for nearly 41% market share in terms of revenue in 2025 driven by investments made in biologics and advanced therapeutics.
• The cell and gene therapy research application segment will witness the highest CAGR in 2025 on the back of growing clinical pipeline of precision medicines.
• Pharmaceutical companies will hold nearly 44% market share in 2025 owing to their widespread outsourcing of cloning, sequencing and gene synthesis projects.

What are the Key Drivers, Restraints, and Opportunities in the United Kingdom DNA and Gene Cloning Services Market?

The biggest growth driver of the United Kingdom DNA and Gene Cloning Services Market includes the fast pace of development of cutting-edge therapeutics, including cell therapy, gene therapy, biologic, and mRNA-based research. Such an impulse was further fueled by steady investments in life sciences as well as automation in DNA synthesis and high throughput cloning. Complex research projects make pharmaceutical and biotech companies turn to service providers in order to clone genes and manipulate them rather than increase their internal laboratory capabilities. Such decisions help save time and money as well as improve scalability and increase the benefits from long-term service agreements, which helps generate revenues.

The greatest barrier to growth is the technical complexity and stringent regulation of genetic engineering and clinical research. Service providers have to make substantial investments into sophisticated lab equipment, quality management system, professional staff of molecular biologists, and regulatory compliance. High costs and long qualification process cannot be solved quickly. Small service providers face difficulties in scaling up, which creates barriers to market entry and adoption of advanced cloning services.

The use of artificial intelligence to automate gene design and synthetic biology is one key opportunity that exists today. Artificial intelligence can be used in sequence optimization for the improvement of construct accuracy, minimization of errors, and quick completion of projects. The growing genomics eco-system in the UK, with collaboration among universities, biotech startups, and pharmaceutical firms, makes it a perfect place for the commercialization of such services.

What Has the Impact of Artificial Intelligence Been on the United Kingdom DNA and Gene Cloning Services Market?

The emerging technologies of artificial intelligence and digital technology are revolutionizing DNA and gene cloning services through automation of molecular biology workflows in terms of efficiency, accuracy, and scale. AI software is becoming popular in automating DNA sequence design, primer selection, vector optimization, and clone validation processes without requiring human involvement in construct development process. LIMS software, robotic liquid handling, and cloud-based data integration systems are making sample tracking, workflow scheduling, and quality control easy in high-throughput laboratories.

Predictive analysis through machine learning models will help in predicting optimal gene constructs, cloning success rate, sequencing errors, and suggesting changes in experiments before carrying out laboratory work. Such predictive technologies will reduce experiment failures, accelerate time required for development, and optimize the laboratory resource usage. Consequently, service providers will be able to offer more number of services within reduced time and low cost to pharma, biotech, and academic organizations engaged in developing biologics, cell therapy, and synthetic biology products.

Nevertheless, the broad application of artificial intelligence in scientific experiments is hampered by the high costs of implementing digital systems in current laboratory settings along with the need to have massive biological databases for training purposes. Another problem is that the experimental protocols used differ, making it difficult to apply models to different institutions within the UK.

Key Market Trends

• Since 2021, pharmaceutical companies have been outsourcing more cloning and gene synthesis work to dedicated service providers to cut down on laboratory costs in-house and speed up research timelines.
• Automation of DNA synthesis processes and cloning systems through robotics have taken place in commercial laboratories from 2020 to 2025, resulting in improved efficiencies as well as reduction in variability of experiments.
• AI-assisted sequence design has become a competitive advantage, with companies like GenScript and Twist Bioscience augmenting their digital offerings to increase efficiency in construct creation.
• Partnerships between biotechnology companies and research institutions have seen an increase since 2022 for translational research and rapid commercialization of novel therapeutics.
• Dedicated sequencing verification and quality control have been added by service providers to adhere to regulatory requirements for gene therapy and biologic drug development programs.
• End-to-end molecular biology services rather than cloning alone is preferred by customers, pushing service providers to expand their research services portfolio.
• There has been a move towards synthetic biology and precision medicine initiatives, which require increased orders of DNA constructs that need to be delivered faster than conventional research projects.
• Cloud-based laboratory information management systems have seen widespread adoption since 2021, with enhanced tracking, data integrity, and collaboration of geographically distributed research groups.
• The competition has moved towards speed, automation, and skills over price alone, compelling global companies to enhance the skills of laboratories and customers in the UK.

United Kingdom DNA and Gene Cloning Services Market Segmentation

By Service: 

Dominating in this segment is Gene Synthesis since the labs require reliable and quick synthesis of custom DNA sequences for drugs, biologics, synthetic biology, and diagnostics. It became more cost-effective to outsource the procedure rather than expand laboratories’ capacities thanks to the fact that gene synthesis platforms allow quick completion of the task and maintain its high quality. Continuous improvements in the efficiency of this process have also helped gain popularity in pharmaceutical companies, biotechs and research centers.

The second biggest market share has Molecular Cloning since construction of recombinant DNA molecules is still essential for functional genomics, protein expression, vaccines research and therapy development. Plasmid preparation and sequencing are also important in order to validate the genetic construct and avoid mistakes in further experiments. The custom DNA services are expected to be the fastest growing segment in the future due to the complexity of research projects that require customized constructs and vectors in molecular engineering.

By End User: 

Pharmaceutical Companies make up the largest share of end-users since their sophisticated drug discovery, biologics development, and cell and gene therapy applications rely on robust services of cloning and gene engineering. Outsourcing helps in cutting down project timescales and scaling up with no need to invest in expensive laboratory resources. Research collaborations are one of the reasons for a more reliable service contract and higher value of projects.

Biotech Firms account for the second biggest segment, including young and innovative companies working on synthetic biology, precision medicine, and other novel technologies. Academic Institutions provide constant demand for molecular biology services due to government-sponsored research projects and cooperation of universities. The highest CAGR is expected for CROs as pharmaceutical and biotech firms outsource their complicated research processes to third parties with flexible capacities and better performance.

What are the Key Use Cases Driving the United Kingdom DNA and Gene Cloning Services Market?

The majority of demands for service comes from the area of drug discovery and biologics development because research teams need reliable DNA constructs for validation of targets, creation of recombinant proteins and conducting of pre-clinical tests. Cloning and gene engineering services can save scientists their time, decreasing lab workload and development period and increasing experimental reliability. Therefore, external service providers have become integral part of pharmaceutical research programs.

Moreover, increased interest towards using these services is expected in cell and gene therapy and molecular diagnostics. Companies in the sphere of biotechnologies are using genetic constructs to develop therapeutics while research institutes are using specialized cloning services for genomic and functional biology studies.

There is scope for innovation in areas like synthetic biology, precision medicine, and CRISPR genome editing technologies. The applications mentioned need tailor-made DNA sequences and cutting-edge molecular engineering technologies in order to advance next-generation therapy platforms. With increased adoption of AI and automation in laboratories, the specialized applications mentioned above will give rise to novel business opportunities during the forecast period.

Which Regions are Driving the United Kingdom DNA and Gene Cloning Services Market Growth?

England enjoys the largest share of market revenues owing to the concentration of pharmaceutical companies, biotechnology companies, contract research organizations, and prestigious universities in the region. Long-term funding for life sciences from the government, advanced lab infrastructure, and cooperation between industries and academic institutes facilitate continuous research activities. Cambridge, Oxford, and London constitute an established innovation network, which draws research investments from within the country and beyond its borders. It is the scientific experience, business cooperation, and special services that help England keep the largest market share.

As far as Scotland is concerned, it takes the second place in terms of market share, however, unlike England, its development is not based on the commercial activities of pharmaceutical firms. On the contrary, it relies on genomics, precision medicine, and university-based research, which ensures steady investment in research cooperation and technological developments. It is the stability of the environment and long-term scientific programs, rather than commercial cycles, that provide consistent demand in the region.

Growth in Wales is forecasted to be highest from 2026 through 2033 due to continued growth in life sciences infrastructure and innovations in biotechnology. Collaboration between universities, healthcare institutions, and new biotech firms has improved their ability to conduct research over the last several years. More investments in translational and therapeutic research have led to opportunities for the provision of outsourcing of DNA and gene cloning services. Such a scenario presents opportunities for potential growth within an emerging life sciences ecosystem.

Who are the Key Players in the United Kingdom DNA and Gene Cloning Services Market and How Do They Compete?

The United Kingdom DNA and Gene Cloning Services Industry is moderately fragmented, where global life science companies operate alongside molecular biology service providers. Technical expertise, speed, quality control, and customization of research solutions have become more valuable than cost alone. The pharmaceutical and biotechnology companies demand from potential partners the ability to handle complicated projects with automated workflow, sequencing verification, and laboratory capacity scaling. This trend has motivated the suppliers to develop their digital technologies and laboratory automation, as well as to increase their service offering.

GenScript's competitive advantage includes a combination of services for gene synthesis, molecular cloning, and protein engineering, which enables research organizations to control multiple phases of the research process within a single partner. Twist Bioscience provides silicon-based DNA synthesis technology and thus achieves better scalability and faster manufacturing of complex DNA structures.

Thermo Fisher Scientific integrates cloning, sequencing, analytical services, and laboratory supplies into a single research platform, thus improving efficiency in purchase and workflows of their clients. Eurofins Scientific concentrates its efforts on testing, sequencing, and laboratory services which comply with high standards, and thus are attractive for pharmaceuticals and biotech firms, operating under compliance standards. Integrated DNA Technologies improves its competitive standing by offering custom oligonucleotides manufacturing, precise gene synthesis, and automation development.

Company List

• GenScript
• Thermo Fisher Scientific
• Eurofins Scientific
• Twist Bioscience
• Azenta Life Sciences
• BioCat
• Synbio Technologies
• Integrated DNA Technologies
• OriGene Technologies
• Bio Basic
• Creative Biogene
• ATUM
• ProteoGenix
• Genewiz
• Bio-Synthesis

Recent Development News

Here are the developments with the full URLs:

In May 2025, Twist Bioscience entered a revised collaboration agreement with Ginkgo Bioworks. The updated three-year agreement granted Twist a license to long DNA technology while strengthening its DNA synthesis capabilities and supporting future synthetic biology applications.

Source: https://investors.twistbioscience.com

In April 2025, GenScript Biotech entered a strategic partnership with NSG Bio. The partnership provides biotechnology startups with preferential access to GenScript's gene synthesis and molecular biology services, helping accelerate research commercialization and innovation.

Source: https://www.genscript.com

In June 2025, ProBio, a GenScript company, opened a flagship plasmid and viral vector manufacturing facility in Hopewell, New Jersey. The investment expanded manufacturing capacity for cell and gene therapy programs and strengthened global support for DNA and gene engineering services.

Source: https://www.genscript.com

What Strategic Insights Define the Future of the United Kingdom DNA and Gene Cloning Services Market?

During the following five to seven years, the United Kingdom DNA and Gene Cloning Services Market will tend towards high integration, automation, and connectivity of the research services provided using the platform, as opposed to individual laboratory solutions. The driving force behind this change will be the growth of pipelines for the development of advanced therapies, which demand faster, scalable, and reproducible workflows of molecular biology. Another, less obvious risk for the market will be increased reliance on the few suppliers of essential reagents, enzymes, and synthetic DNA globally. This might increase the cost of running research due to delays in projects caused by the disruption of these supply chains. Another promising direction for the future would be the use of gene design services enhanced by artificial intelligence in combination with cloud-based laboratories. Companies will benefit from faster optimization of constructs and better collaboration with other research institutions.

United Kingdom DNA and Gene Cloning Services Market Report Segmentation

By Service

• Gene Synthesis
• Molecular Cloning
• Plasmid Preparation
• Sequencing
• Custom DNA Services
• Others

By End User

• Pharmaceutical Companies
• Biotechnology Firms
• Academic Institutes
• CROs (Contract Research Organizations)
• Others